A Novel M1 PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity-Reference-Cited by-同舟云学术

A Novel M1 PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity

Published:2018-04-27 Issue:9 Volume:9 Page:2274-2285
ISSN:1948-7193
Container-title:ACS Chemical Neuroscience
language:en
Short-container-title:ACS Chem. Neurosci.

Author:

Rook Jerri M.,Bertron Jeanette L.,Cho Hyekyung P.,Garcia-Barrantes Pedro M.,Moran Sean P.^ORCID,Maksymetz James T.,Nance Kellie D.^ORCID,Dickerson Jonathan W.,Remke Daniel H.,Chang Sichen,Harp Joel M.,Blobaum Anna L.,Niswender Colleen M.,Jones Carrie K.,Stauffer Shaun R.,Conn P. Jeffrey,Lindsley Craig W.^ORCID

Funder

National Institute of Mental Health

Publisher

American Chemical Society (ACS)

Subject

Cell Biology,Cognitive Neuroscience,Physiology,Biochemistry,General Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acschemneuro.8b00131

Reference41 articles.

1. Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease

2. The antipsychotic potential of muscarinic allosteric modulation

3. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies